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Abstract Alzheimer’s disease (AD) is a progressive
neurodegenerative disorder, causing changes in memory,
thinking, and other dysfunction of brain functions. More
and more people are suffering from the disease. Early
neuroimaging techniques of AD are needed to develop.
This review provides a preliminary summary of the various
neuroimaging techniques that have been explored for
in vivo imaging of AD. Recent advances in magnetic res-
onance (MR) techniques, such as functional MR imaging
(fMRI) and diffusion MRI, give opportunities to display
not only anatomy and atrophy of the medial temporal lobe,
but also at microstructural alterations or perfusion distur-
bance within the AD lesions. Positron emission tomogra-
phy (PET) imaging has become the subject of intense
research for the diagnosis and facilitation of drug devel-
opment of AD in both animal models and human trials due
to its non-invasive and translational characteristic. Fluo-
rodeoxyglucose (FDG) PET and amyloid PET are applied
in clinics and research departments. Amyloid beta (Ab)
imaging using PET has been recognized as one of the most
important methods for the early diagnosis of AD, and
numerous candidate compounds have been tested for Ab
imaging. Besides in vivo imaging method, a lot of ex vivo
modalities are being used in the AD researches. Mul-
tiphoton laser scanning microscopy, neuroimaging of
metals, and several metal bioimaging methods are also
mentioned here. More and more multimodality and multi-
parametric neuroimaging techniques should improve our
understanding of brain function and open new insights into
the pathophysiology of AD. We expect exciting results will
emerge from new neuroimaging applications that will
provide scientific and medical benefits.
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1 Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder that gradually destroys brain cells, causing
changes in memory, thinking, and other dysfunction of
brain functions [1]. AD is considered to a prolonged pre-
clinical stage where neuropathological changes precede the
clinical symptoms [2]. An estimation of 35 million people
worldwide is living with this disease. If effective treat-
ments are not discovered in a timely fashion, the number of
AD cases is anticipated to rise to 113 million by 2050 [3].
Amyloid beta (Ab) and tau are two of the major
biomarkers of AD, and have important and different roles
in association with the progression of AD pathophysiology.
Jack et al. established hypothetical models of the major
biomarkers of AD. By renewing and modifying the models,
they found that the two major proteinopathies underlying
AD biomarker changes, Ab and tau, may be initiated
independently in late onset AD where they hypothesize that
an incident Ab pathophysiology can accelerate an ante-
cedent limbic and brainstem tauopathy [4]. MRI technique
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was used in the article, which revealed that the level of Ab
load was associated with a shorter time-to-progression of
AD [5]. This warrants an urgent need to develop early
neuroimaging techniques of AD neuropathology that can
detect and predict the disease before the onset of dementia,
monitor therapeutic efficacy in halting and slowing down
progression in the earlier stage of the disease.
There have been various reports on the imaging assess-
ments of AD. Some measurements reflect the pathology of
AD directly, including positron emission tomography
(PET) amyloid imaging and cerebrospinal fluid (CSF) beta-
amyloid 42 (Ab42), while others reflect neuronal injury
associated with AD indirectly, including CSF tau (total and
phosphorylated tau), fluorodeoxy-D-glucose (FDG)-PET,
and MRI. AD Neuroimaging Initiative (ADNI) has been to
establish the optimal panel of clinical assessments, MRI and
PET imaging measures, as well as other biomarkers from
blood and CSF, to inform clinical trial design for AD
therapeutic development. At the same time, it has been
highly productive in generating a wealth of data for eluci-
dating disease mechanisms occurring during early stages of
preclinical and prodromal AD [6].
Single neuroimaging often reflects limit information of
AD. As a result, multimodal neuroimaging is widely used
in neuroscience researches, as it overcomes the limitations
of individual modalities. Multimodal multiparametric
imaging mean the combination of different imaging tech-
niques, such as PET, MRI, simultaneously or separately.
The multimodal multiparametric imaging enables the
visualization and quantitative analysis of the alterations in
brain structure and function, such as PET/CT, and PET/
MRI. [7]. In this review article, we summarize and discuss
the main applications, findings, perspectives as well as
advantages and challenges of different neuroimaging in
AD, especially MRI and PET imaging.
2 Magnetic resonance imaging
MRI demonstrates specific volume loss or cortical atrophy
patterns with disease progression in AD patients [8–10].
There are several MRI techniques and analysis methods
used in clinical and scientific research of AD. Recent
advances in MR techniques, such as functional MRI
(fMRI) and diffusion MRI, depict not only anatomy and
atrophy of the medial temporal lobe (MTL), but also
microstructural alterations or perfusion disturbance within
this region.
2.1 Functional MRI
Because of the cognitive reserve (CR), the relationship
between severity of AD patients’ brain damage and
corresponding clinical symptoms is not always paralleled
[11, 12]. Recently, resting-state fMRI (RS-fMRI) is pop-
ular for its ability to map brain functional connectivity non-
invasively [13]. By using RS-fMRI, Bozzali et al. reported
that the CR played a role in modulating the effect of AD
pathology on default mode network functional connectiv-
ity, which account for the variable clinical symptoms of
AD [14]. Moreover, AD patients with higher educated
experience were able to recruit compensatory neural
mechanisms, which can be measured using RS-fMRI.
Arterial spin-labeled (ASL) MRI is another functional
brain imaging modality, which measures cerebral blood
flow (CBF) by magnetically labeled arterial blood water
following through the carotid and vertebral arteries as an
endogenous contrast medium. Several studies have con-
cluded the characteristics of CBF changes in AD patients
using ASL-MRI [15–17].
At some point in time, sufficient brain damage accu-
mulates to result in cognitive symptoms and impairment.
Mild cognitive impairment (MCI) is a condition in which
subjects are usually only mildly impaired in memory with
relative preservation of other cognitive domains and
functional activities and do not meet the criteria for
dementia [18], or as the prodromal state AD [19]. MCI
patients are at a higher risk of developing AD and up to
15 % convert to AD per year [18]. Binnewijzend et al. have
reported the pseudocontinuous ASL could distinguish both
MCI and AD from healthy controls, and be used in the
early diagnosis of AD [20]. In their continuous study, they
used quantitative whole brain pseudocontinuous ASL to
compare regional CBF (rCBF) distribution patterns in
different types of dementia, and concluded that ASL-MRI
could be a non-invasive and easily accessible alternative to
FDG-PET imaging in the assessment of CBF of AD
patients [21].
2.2 Structure MRI
Structural MRI (sMRI) has already been a reliable imaging
method in the clinical diagnosis of AD, characterized as
gray matter reduction and ventricular enlargement in
standard T1-weighted sequences [9]. Locus coeruleus (LC)
and substantia nigra (SN) degeneration was seen in AD. By
using new quantitative calculating method, Chen et al.
presented a new quantitative neuromelanin MRI approach
for simultaneous measurement of locus LC and SN of
brainstem in living human subjects [22]. The approach they
used demonstrated advantages in image acquisition, pre-
processing, and quantitative analysis. Numerous transgenic
animal models of amyloidosis are available, which can
manipulate a lot of neuropathological features of AD pro-
gression from the deposition of b-amyloid [23]. Braakman
et al. demonstrated the dynamics of amyloid plaque
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formation and development in a serial MRI study in a
transgenic mouse model [24]. Increased iron accumulation
in gray matter is frequently observed in AD. Because of the
paramagnetic nature of iron, MRI shows nice potential in
the investigating iron levels in AD [25]. Quantitative MRI
was shown high sensitivity and specificity in mapping
cerebral iron deposition, and helped in the research on AD
diagnosis [26].
The imaging patterns are always associated with the
pathologic changes, such as specific protein markers.
Spencer et al. manifested the relationship between quanti-
tative T1 and T2 relaxation time changes and three
immunohistochemical markers: b-amyloid, neuron-specific
nuclear protein (a marker of neuronal cell load), and
myelin basic protein (a marker of myelin load) in AD
transgenic mice [27].
High-field MRI has been successfully applied to imag-
ing plaques in transgenic mice for over a decade without
contrast agents [24, 28–30]. Sillerud et al. devised a
method using blood–brain barrier penetrating, amyloid-
targeted, superparamagnetic iron oxide nanoparticles
(SPIONs) for better imaging of amyloid plaque [31]. Then,
they successfully used this SPION-MRI to assess the drug
efficacy on the 3D distribution of Ab plaques in transgenic
AD mouse [32].
2.3 Diffusion MRI
Diffusion-weighted imaging (DWI) is a sensitive tool that
allows quantifying of physiologic alterations in water dif-
fusion, which result from microscopic structural changes.
Diffusion tensor imaging (DTI) is a well-established and
commonly employed diffusion MRI technique in clinical
and research on neuroimaging studies, which is based on a
Gaussian model of diffusion processes [33]. In general, AD
is associated with widespread reduced fractional anisotropy
(FA) and increased mean diffusivity (MD) in several
regions, most prominently in the frontal and temporal
lobes, and along the cingulum, corpus callosum, uncinate
fasciculus, superior longitudinal fasciculus, and MTL-as-
sociated tracts than healthy controls [34–37]. Acosta-
Cabronero et al. reported increased axial diffusivity and
MD in the splenium, which were the earliest abnormalities
in AD [38]. FA and radial diffusivity (DR) differences in
the corpus callosum, cingulum, and fornix were found to
separate individuals with MCI who converted to AD from
non-converters [39]. DTI was also found to be a better
predictor of AD-specific MTL atrophy when compared to
CSF biomarkers [40]. These findings suggested the
potential clinical utility of DTI as early biomarkers of AD
and its progression. However, an increase in MD and DR
and a decrease in FA with advancing age in selective brain
regions have been previously reported [41, 42]. Diffusion
MRI can be also used in the classifying of various stages of
AD. Multimodal classification method, which combined
fMRI and DTI, separated more MCI from healthy controls
than single approaches [43].
In recent years, tau has emerged as a potential target for
therapeutic intervention. Tau plays a critical role in the
neurodegenerative process forming neurofibrillary tangles,
which is a major hallmark of AD and correlates with
clinical disease progression. Wells et al. applied multi-
parametric MRI, containing high-resolution structure MRI
(sMRI), a novel chemical exchange saturation transfer
(CEST) MRI, DTI, and ASL, and glucose CEST to mea-
sure changes of tau pathology in AD transgenic mouse
[44].
Besides DWI MRI, perfusion-weighted imaging (PWI)
is another advanced MR technique, which could measure
the cerebral hemodynamics at the capillary level. Zimny
et al. evaluated the correlation of MTL with both DWI and
PWI in AD and MCI patients [45].
3 Positron emission tomography
PET is a specific imaging technique applying in researches
of brain function and neurochemistry of small animals,
medium-sized animals, and human subjects [46–48]. As a
particular brain imaging technique, PET imaging has
become the subject of intense research for the diagnosis
and facilitation of drug development of AD in both animal
models and human trials due to its non-invasive and
translational characteristic. PET with various radiotracers
is considered as a standard non-invasive quantitative
imaging technique to measure CBF, glucose metabolism,
and b-amyloid and tau deposition.
3.1 FDG-PET
To date, 18F-FDG is one of the best and widely used
neuroimaging tracers of PET, which employed for research
and clinical assessment of AD [49]. Typical lower FDG
metabolism was shown in the precuneus, posterior cingu-
late, and temporal and parietal cortex with progression to
whole brain reductions with increasing disease progress in
AD brains [50, 51]. FDG-PET imaging reflects the cerebral
glucose metabolism, neuronal injury, which provides
indirect evidence on cognitive function and progression
that cannot be provided by amyloid PET imaging.
Schraml et al. [52] identified a significant association
between hypometabolic convergence index and phenotypes
using ADNI data. Some researchers also used 18F-FDG-
PET to analyze genetic information with multiple
biomarkers to classify AD status, predicting cognitive
decline or MCI to AD conversion [53–55]. Trzepacz et al.
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[56] reported multimodal AD neuroimaging study, using
MRI, 11C-PiB PET, and 18F-FDG-PET imaging to predict
MCI conversion to AD along with APOE genotype. Zhang
et al. [57] compared the genetic modality single-nucleotide
polymorphism (SNP) with sMRI, 18F-FDG-PET, and CSF
biomarkers, which were used to differentiate healthy con-
trol, MCI, and AD. They found FDG-PET is the best
modality in terms of accuracy.
3.2 Amyloid beta PET
Ab, the primary constituent of senile plaques, and tau
tangles are hypothesized to play a primary role in the
pathogenesis of AD, but it is still hard to identify the
fundamental mechanisms [58–60]. Ab plaque in brain is
one of the pathological hallmarks of AD [61, 62]. Accu-
mulation of Ab peptide in the cerebral cortex is considered
one cause of dementia in AD [63]. Numerous studies have
involved in vivo PET imaging assessing cortical b-amyloid
burden [64–66].
Ab imaging using PET has been recognized as one of
the most important methods for the early diagnosis of AD
[67]. Numerous candidate compounds have been tested for
Ab imaging, such as 11C-PiB [68], 18F-FDDNP [69], 11C-
SB-13 [70], 18F-BAY94-9172 [71], 18F-AV-45 [72], 18F-
flutemetamol [73, 74], 11C-AZD2184 [75], and 18F-
ADZ4694 [76], 11C-BF227 and 18F-FACT [77].
Several amyloid PET studies examined genotypes,
phenotypes, or gene–gene interactions. Ramanan et al. [78]
reported the GWAS results with 18F-AV-45 reflecting the
cerebral amyloid metabolism in AD for the first time.
Swaminathan et al. [79] revealed the association between
plasma Ab from peripheral blood and cortical amyloid
deposition on 11C-PiB. Hohman et al. [80] reported the
relationship between SNPs involved in amyloid and tau
pathophysiology with 18F-AV-45 PET.
Among the PET tracers, 11C-PiB, which has a high
affinity for fibrillar Ab, is a reliable biomarker of under-
lying AD pathology [68, 81]. It shows cortical uptake well
paralleled with AD pathology [82, 83], has recently been
approved for use by the Food and Drug Administration
(FDA, April 2012) and the European Medicines Agency
(January 2013). 18F-GE-067 (flutemetamol) and 18F-
BAY94-9172 (florbetaben) have also been approved by the
US FDA in the last 2 years [84, 85].
18F-Florbetapir (also known as 18F-AV-45) exhibits
high affinity specific binding to amyloid plaques. 18F-AV-
45 labels Ab plaques in sections from patients with
pathologically confirmed AD [72].
It was reported in several research groups that 18F-AV-45
PET imaging showed a reliability of both qualitative and
quantitative assessments in AD patients, and Ab? increased
with diagnostic category (healthy control\MCI\AD)
[82, 86, 87]. Johnson et al. used 18F-AV-45 PET imaging to
evaluate the amyloid deposition in both MCI and AD
patients qualitatively and quantitatively, and found that
amyloid burden increased with diagnostic category
(MCI\AD), age, and APOEe4 carrier status [88]. Payoux
et al. reported the equivocal amyloid PET scans using 18F-
AV-45 associated with a specific pattern of clinical signs in a
large population of non-demented older adults more than
70 years old [89].
More and more researchers consider combination and
comparison of multiple PET tracers targeting amyloid
plaque imaging together. Bruck et al. compared the prog-
nostic ability of 11C-PiB PET, 18F-FDG-PET, and quan-
titative hippocampal volumes measured with MR imaging
in predicting MCI to AD conversion. They found that the
FDG-PET and 11C-PiB PET imaging are better in pre-
dicting MCI to AD conversion [90]. Hatashita et al. used
11C-PiB and FDG-PET imaging to identify MCI due to
AD, 11C-PiB showed a higher sensitivity of 96.6 %, and
FDG-PET added diagnostic value in predicting AD over a
short period [91].
Besides, new Ab imaging agents were radiosynthesized.
Yousefi et al. radiosynthesized a new Ab imaging agent
18F-FIBT, and compared the three different Ab-targeted
radiopharmaceuticals for PET imaging, including 18F-
FIBT, 18F-florbetaben, and 11C-PiB [92]. 11C-AZD2184
is another new PET tracer developed for amyloid senile
plaque imaging, and the kinetic behavior of 11C-AZD2184
is suitable for quantitative analysis and can be used in
clinical examination without input function [75, 93, 94].
4 Multimodality imaging: PET/MRI
Several diagnostic techniques, including MRI and PET, are
employed for the diagnosis and monitoring of AD [95].
Multimodal imaging could provide more information in the
formation and key molecular event of AD than single
method. It drives the progression of neuroimaging research
due to the recognition of the clinical benefits of multimodal
data [96], and the better access to hybrid devices, such as
PET/MRI [97].
Maier et al. evaluated the dynamics of 11C-PiB PET,
15O-H2O-PET, and ASL-MRI in transgenic AD mice and
concluded that the AD-related decline of rCBF was caused
by the cerebral Ab angiopathy [98]. Edison et al. system-
atically compared 11C-PiB PET and MRI in AD, MCI
patients, and controls. They thought that 11C-PiB PET was
adequate for clinical diagnostic purpose, while MRI
remained more appropriate for clinical research [99]. Zhou
et al. investigated the interactions between multimodal
PET/MRI in elder patients with MCI, AD, and healthy
controls, and confirmed the invaluable application of
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amyloid PET and MRI in early diagnosis of AD [100]. Kim
et al. reported that Ab-weighted cortical thickness, which
incorporates data from both MRI and amyloid PET imag-
ing, is a consistent and objective imaging biomarker in AD
[101].
5 Other imaging modalities
Multiphoton non-linear optical microscope imaging systems
using ultrafast lasers have powerful advantages such as label-
free detection, deep penetration of thick samples, high sensi-
tivity, subcellular spatial resolution, 3D optical sectioning,
chemical specificity, and minimum sample destruction [102,
103]. Coherent anti-Stokes–Raman scattering (CARS), two-
photon excited fluorescence (TPEF), and second-harmonic
generation (SHG) microscopy are the most widely used
biomedical imaging techniques [104–106].
Some researchers have reported in vivo imaging of
senile plaque and collagen using multiphoton laser scan-
ning microscopy or auto-fluorescence and SHG images in
AD mouse model [107, 108]. Lee et al. developed a mul-
timodal multiphoton non-linear optical microspectroscopy
imaging system based on a small-diameter probe with
gradient-index lenses combing CARS, TPEF, and SHG
into one platform for imaging distinct molecular structures
and components of brain tissue associated with AD trans-
formation [109].
Metal dyshomeostasis is frequently observed in AD due
to anomalous binding of metals such as iron (Fe), copper
(Cu), and zinc (Zn), or impaired regulation of redox-active
metals inducing the neuronal damage. Neuroimaging of
metals in a variety of intact brain cells and tissues is
emerging as an important tool for increasing our under-
standing of the role of metal dysregulation in AD. Braidy
et al. reviewed the metal bioimaging in AD [110]. Several
imaging techniques, such as laser ablation inductively
coupled mass spectrometry (MS), X-ray fluorescence
microscopy, MALDI imaging mass spectrometry (MALDI-
MS), and Fourier transform infrared spectroscopy,, have
been used to study in AD [111–114]. Several limitations of
metal bioimaging, such as lower spatial resolution and
detection sensitivity, make it not as valuable as PET and
MRI imaging.
6 Perspective of neuroimaging in precision imaging
Precision medicine is a phrase that is often used to describe
how genetic information about a person’s disease is being
used to diagnose or treat their disease. Understanding the
genetic changes that are in AD formation is leading to more
effective treatment strategies. The prospect of a
personalized or precision medicine for AD, and for its
incorporation in therapeutic trial design, is predicated on
the ability to use an individual’s genetic profile to refine
predisposition to disease, characteristics such as likely rate
of progression, and predicted therapeutic and side effect
responses to various therapeutic strategies [115]. At pre-
sent, the genetic data associated with AD clinical drug
development were mainly focused on APOE, which was
commonly used as stratification factor or covariate to
adjust for heterogeneity [116, 117].
Ultimately, imaging-genetic endophenotype studies may
provide a link between genetics and disease topography by
elucidating those areas of the brain most associated with
known and potential pathological genotypes. APOE geno-
type may be one important factor contributing to hetero-
geneity in sporadic AD, as non-e4 status among EOAD
patients correlates with atypicality [118].
7 Conclusion
This review provides a preliminary summary of the various
neuroimaging techniques that have been explored for
in vivo imaging of AD. MRI and PET imaging are still the
mainly used technique in the detection, assessment of AD.
From a scientific perspective, more and more multi-
modality and multiparametric neuroimaging techniques
should improve our understanding of brain function and
open new insights into the pathophysiology of AD. We
expect exciting results will emerge from new neuroimaging
applications that will provide scientific and medical
benefits.
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